Trial Profile

A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Dec 2024 Status changed from not yet recruiting to recruiting.
17 Oct 2024 Status changed from planning to not yet recruiting.
08 Sep 2024 According to an Ascentage Pharma media release, the company will present the latest clinical data of olverembatinib (HQP1351), in patients with succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST), in a Mini Oral at the 2024 European Society of Medical Oncology (ESMO) Congress held from September 13 to 17 in Barcelona, Spain. The presentation will be done on September 13, 2024, 16:30 -16:35 CEST, by Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center (no. 1722MO).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com